Giant-cell arteritis and threatened vision

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Giant-cell arteritis is an inflammatory disease of medium and large arteries that predominantly affects older adults. In ophthalmic practice its importance lies in interruption of the arterial supply to the optic nerve and other ocular structures. Arteritic anterior ischaemic optic neuropathy can cause profound permanent loss, and the fellow eye may be threatened even if only one eye is currently symptomatic.

The immediate objective is to prevent further ischaemic injury while arranging confirmation. Treatment is justified by a sufficiently convincing clinical assessment and should not be postponed for a temporal-artery biopsy or vascular ultrasound. The subsequent pathway must revisit the diagnosis, evaluate systemic arterial involvement where indicated and manage the substantial consequences of prolonged glucocorticoid exposure.

Key points

Consider giant-cell arteritis in adults over fifty with a new headache, jaw claudication, scalp tenderness or compatible visual symptoms.
Ocular disease may occur without a prominent headache or the complete systemic symptom pattern.
Obtain inflammatory markers and blood counts promptly when feasible, but treatment must not wait for results when clinical suspicion is strong.
BSR guidance permits intravenous methylprednisolone 500 mg–1 g daily for up to three days for acute or intermittent visual loss, followed by oral treatment.
If intravenous treatment is not immediately possible, BSR permits oral prednisolone 60–100 mg daily for up to three days as an initial bridge; do not delay oral treatment to arrange intravenous therapy.
For GCA without visual ischaemia, the usual BSR initial oral prednisolone dose is 40–60 mg daily, followed by an individualised taper.
Aspirin or anticoagulation is not routinely indicated solely because GCA is present; use established independent vascular indications.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Immune-mediated arterial inflammation

GCA involves inflammatory injury in medium and large arteries, particularly in older adults. Its precise initiating cause is incompletely understood, and a compatible clinical pattern is more useful than searching for one identifiable trigger.

Cranial and extracranial involvement

Disease can involve branches supplying the head and eyes as well as larger arteries elsewhere. The distribution explains why cranial symptoms, polymyalgia features and limb or systemic manifestations may occur in different combinations.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Narrowing of the arterial lumen
Inflammation and vessel-wall remodelling impair blood flow through affected arteries. Tissue supplied downstream becomes vulnerable to ischaemia, particularly when collateral circulation cannot compensate for the reduction in perfusion.
2
Optic-nerve head ischaemia
Compromise of the arterial supply to the anterior optic nerve can cause swelling and severe loss of visual function. The injury may become permanent rapidly, making treatment before further events more valuable than waiting for established damage.
3
Transient and permanent ocular events
Intermittent reductions in ocular perfusion may cause brief visual blackouts before sustained infarction occurs. Diplopia can also reflect ischaemic involvement, so complete symptom resolution does not remove concern for the underlying arterial disease.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Cranial ischaemic symptoms

Ask about new headache, scalp sensitivity, jaw pain or fatigue brought on by chewing, and tongue symptoms. Jaw claudication is more concerning than nonspecific temporomandibular discomfort. The absence of any one feature does not exclude disease when other findings support arteritis.

Visual warning episodes

Transient monocular dimming or blackout, new diplopia and persistent visual loss all require urgent attention. Record timing, duration and whether the symptom was truly monocular. A normal interval acuity measurement after a transient episode does not establish that the eye is safe.

Arteritic optic neuropathy

Severe visual loss with an afferent pupil defect and a pale swollen optic disc is concerning for arteritic anterior ischaemic optic neuropathy. The ophthalmic examination also considers retinal arterial ischaemia and other causes; a painless presentation is not reassuring.

Systemic and large-artery clues

Ask about weight loss, fever, fatigue, shoulder or hip-girdle stiffness and limb claudication. Examine pulses and blood pressure as clinically appropriate. Polymyalgia symptoms can coexist, but their absence does not exclude cranial disease or threatened vision.

Occult or atypical disease

Some patients present mainly with ocular ischaemia and lack a classic systemic history. Normal inflammatory markers reduce support for the diagnosis but cannot independently exclude it. Interpret age, symptoms, examination and investigations together rather than relying on a single result.

Red flags requiring action

Suspected giant-cell arteritis with new visual loss or diplopia needs same-day ophthalmic assessment and immediate glucocorticoid treatment.
Transient visual loss is an ischaemic warning and should not be downgraded because vision has returned before examination.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Immediate clinical and ophthalmic assessmentFirst step
Why
Determine whether ocular ischaemia is present and protect remaining vision.
Interpretation and limitations
Record acuity in each eye, pupils, fields and dilated optic-disc findings through urgent ophthalmic assessment. New visual loss or diplopia in suspected GCA merits assessment as soon as possible on the same calendar day, with treatment initiated while arrangements proceed.
02
CRP, ESR and full blood count
Why
Support the inflammatory assessment and establish useful baseline measures before treatment.
Interpretation and limitations
Raised inflammatory markers and thrombocytosis can support GCA, but neither a normal result nor an isolated elevation settles the diagnosis. Take blood before glucocorticoids when practical without causing a clinically important delay.
03
Temporal and other artery ultrasound or temporal-artery biopsy
Why
Obtain objective evidence through an experienced fast-track diagnostic service.
Interpretation and limitations
Select the test or combination according to local expertise and the clinical question. A negative result needs interpretation against pre-test suspicion, sampling limitations and prior treatment; it should not automatically terminate therapy in a strongly suggestive visual presentation.
04
Baseline treatment safety and selected large-vessel assessment
Why
Identify glucocorticoid risks and investigate extracranial arterial disease when indicated.
Interpretation and limitations
Review glucose, blood pressure, renal and liver function, fracture risk and relevant infection history. Additional vascular imaging is guided by the clinical pattern and specialist assessment rather than used to delay urgent treatment of cranial ischaemia.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Non-arteritic ischaemic optic neuropathy

NAION also causes sudden optic-nerve dysfunction, often in patients with vascular risks. The distinction matters because suspected arteritic disease requires immediate systemic treatment, and age or a painless presentation cannot decide between them alone.

Embolic retinal ischaemia

Carotid or cardiac embolic disease can cause transient monocular loss or retinal arterial occlusion. Vascular assessment may be required alongside evaluation for arteritis when the clinical picture leaves both possibilities plausible.

Other headache and jaw disorders

Migraine, dental disease and temporomandibular disorders can imitate parts of the history. New symptoms in an older adult, especially with visual change or exertional jaw discomfort, require careful assessment rather than automatic attribution.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Sight emergencyAcute or intermittent visual lossFirst stepGCA is suspected and the patient has new persistent or transient visual ischaemic symptoms.

1Start glucocorticoids immediately and arrange ophthalmology as soon as possible on the same calendar day with urgent medical or rheumatology coordination.
2For acute or intermittent visual loss, consider the BSR intravenous methylprednisolone regimen of 500 mg–1 g daily for up to three consecutive days, then oral treatment.
3If intravenous therapy cannot be delivered immediately, use urgent oral prednisolone rather than waiting; BSR allows 60–100 mg daily for up to three days in this setting.
4Obtain diagnostic confirmation and reassess both eyes while explaining that established loss may not recover even though treatment protects remaining vision.

02Urgent treatmentSuspected disease without visual ischaemiaThe clinical picture supports GCA but there is no current ocular ischaemic feature.

1Arrange an urgent GCA diagnostic pathway and start oral prednisolone, usually 40–60 mg daily under the BSR initial regimen.
2Obtain appropriate baseline blood tests and arrange ultrasound or biopsy promptly without delaying necessary treatment.
3Explain that any new visual symptom or diplopia requires immediate contact and same-day ophthalmic reassessment.
4Once disease control is established, agree an individualised taper and follow-up plan rather than stopping abruptly when headache resolves.

03Long-termMaintain control and minimise treatment harmThe diagnosis has been assessed and ongoing treatment or relapse management is required.

1Monitor for recurrent cranial symptoms, visual change, polymyalgia symptoms and clinically relevant large-vessel manifestations.
2Assess glucocorticoid complications and provide bone protection, vaccination and adrenal-risk advice according to individual risk and the wider treatment plan.
3Consider specialist steroid-sparing treatment for appropriate relapsing or refractory disease, using current NHS eligibility requirements.
4Use antiplatelet or anticoagulant therapy for a separate established indication rather than prescribing it automatically for the arteritis label.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Rapidly suppress arterial inflammation when visual ischaemia threatens further irreversible injury.

Methylprednisolone for threatened vision

BSR conditionally recommends 500 mg–1 g intravenously once daily for up to three consecutive days for acute or intermittent visual loss, followed by oral glucocorticoids.

Use an urgent supervised specialist pathway with monitoring of glucose, blood pressure, mental state and infection risk. Intravenous access or scheduling must not postpone initial oral treatment when immediate intravenous delivery is unavailable.

Provide immediate systemic treatment while urgent ophthalmic and intravenous-treatment arrangements are made.

Prednisolone when intravenous therapy is delayed

For acute or intermittent visual loss when intravenous treatment is not immediately possible, BSR permits 60–100 mg orally once daily for up to three days, then specialist-directed continuation.

This is the visual-ischaemia bridge regimen, not a routine prolonged maintenance dose. Review diabetes, psychiatric history, infection and gastrointestinal risks without allowing routine checks to delay sight-saving treatment.

Treat clinically suspected GCA when acute visual ischaemia is absent.

Prednisolone without visual ischaemia

Usually start 40–60 mg orally once daily, then taper according to disease control and the specialist plan rather than using a fixed short course.

Long treatment can cause infection, hyperglycaemia, hypertension, osteoporosis and adrenal suppression. Establish monitoring and protection early, and give clear instructions about relapse, intercurrent illness and avoiding abrupt withdrawal.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Irreversible bilateral visual loss

Ischaemic injury can affect one eye and subsequently threaten the other. Prompt suppression of inflammation aims to preserve remaining vision, although it may not reverse established optic-nerve infarction.

Systemic arterial complications

Large-vessel involvement can produce limb ischaemic symptoms and later aortic complications in some patients. The need for further vascular assessment is determined by the disease pattern and specialist follow-up.

Glucocorticoid treatment morbidity

Prolonged systemic therapy can affect bone, glucose control, blood pressure, infection risk, mood and adrenal function. Monitoring and preventive measures form part of disease management rather than an optional addition after symptoms improve.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

At each review, ask directly about transient or persistent visual change, diplopia, jaw symptoms and new headache rather than relying solely on inflammatory markers.
Review glucose, blood pressure, weight, mood, infection and bone health during glucocorticoid treatment, adjusting the prevention plan to the dose and duration.
Monitor for relapse during tapering and arrange urgent reassessment if ocular symptoms occur; do not advise the patient simply to wait for the next routine appointment.
Coordinate ophthalmology and rheumatology follow-up so visual recovery, disease activity, diagnostic confidence and treatment toxicity are assessed together.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Tocilizumab eligibility is specific

NICE TA518 supports tocilizumab for adults with relapsing or refractory GCA who have not previously received it, initially alongside tapering glucocorticoids. The recommendation limits treatment to at most one uninterrupted year and includes the applicable commercial arrangement; specialist selection is essential.

Visual treatment aims at prevention

A profoundly ischaemic optic nerve may not regain useful function despite prompt therapy. Starting treatment still matters because the other eye and other arterial territories may remain at risk, and apparent failure to restore sight does not show that treatment was unnecessary.

Markers are part of a clinical picture

Inflammatory results support diagnosis and follow-up but have limitations, including effects of treatment and other illnesses. A convincing new ocular ischaemic event deserves urgent reassessment even when a recent blood test appeared satisfactory.

Antithrombotic treatment needs its own indication

BSR does not recommend routine antiplatelet or anticoagulant treatment solely for GCA. A patient with another vascular indication may still need it, with the benefits and bleeding risks assessed through the relevant prevention pathway.

11Common pitfallsFrequent interpretation and management errors.

01
Waiting for biopsy or ultrasound confirmation before treating a convincing threatened-vision presentation.
02
Treating a transient blackout as low risk because acuity is normal at the consultation.
03
Using the non-visual 40–60 mg starting range as a reason to delay specialist assessment of acute visual ischaemia.
04
Stopping glucocorticoids abruptly after headache improves or prescribing aspirin automatically to every patient with GCA.